Collaboration between Camgenium and Cardiac Tech for advanced post-surgical care using Pace-Protect system
New Medical Device Pace-Protect Set for Clinical Trials
A groundbreaking medical device named Pace-Protect, designed for real-time monitoring of temporary pacemakers, is preparing for clinical trials. This innovative device, developed by Camgenium in partnership with Cardiac Tech, aims to prevent adverse events following open-heart surgery.
Pace-Protect utilizes Camgenium's Soft Silicon technology for data transmission, ensuring world-class data security and patient confidentiality. The Soft Silicon mesh network technology, never before deployed in a clinical environment, offers high resilience, ensuring individual Pace-Protect devices never lose contact with the cloud.
The device is designed to address the unmet need for safer temporary pacemakers. It continuously assesses pacing efficacy and lead integrity, detects early signs of complications such as lead displacement or infection, and alerts clinical staff promptly to adverse events or device irregularities.
In emergencies, Pace-Protect allows for real-time patient electrogram (EGM) data transmission at high data rates, enabling swift action by the clinical team. The device is also equipped with AI-enabled features and remote data analysis, transforming cardiac pacing by enabling smarter patient management and early detection of arrhythmia risks or device issues.
Research indicates that there are roughly 1,500 serious adverse events (SAEs) reported each year following open-heart surgery in the US alone, attributable to the management of temporary pacemakers. The Pace-Protect system, with its real-time monitoring and alerts, addresses this issue by providing a safer solution that can ultimately prevent SAEs.
Pace-Protect is a safety device designed to monitor all aspects of temporary pacing and report acute changes immediately to clinicians. It represents a significant step forward in the field of cardiac pacing, integrating real-time telemetry and predictive analytics into temporary pacing systems to enhance safety and outcomes after open-heart surgery.
Camgenium, a leading medical software engineering company, has integrated its proprietary Soft Silicon medical device grade two-way device communications technology for data transmission into the Pace-Protect prototype. Soft Silicon is a highly sophisticated mesh architecture for communications using BLE and Wi-Fi, cellular, NFC, and LORA.
The company is partnering with MedTech innovator Cardiac Tech to develop Pace-Protect, aiming to bring this life-saving device to patients. The partnership between Camgenium and Cardiac Tech underscores a shared commitment to improving patient safety during the vulnerable post-surgical period.
As Pace-Protect moves towards clinical trials, it represents a promising solution for the real-time monitoring of temporary pacemakers, with the potential to significantly reduce the risk of adverse events following open-heart surgery.
- The upcoming clinical trials for the digital health device, Pace-Protect, are a significant step forward in the field of medical-conditions such as cardiovascular-health, as it aims to prevent adverse events following open-heart surgery through real-time monitoring and alert systems.
- The science behind Pace-Protect's functionality includes the use of technology like Camgenium's Soft Silicon technology for secure data transmission, AI-enabled features, and remote data analysis, all of which contribute to smarter patient management and early detection of arrhythmia risks or device issues.
- In the realm of health-and-wellness, the success of Pace-Protect's clinical trials could potentially lead to a reduction in serious adverse events (SAEs) reported each year in the US alone, as it addresses the unmet need for safer temporary pacemakers.
